May 12, 2017 07:38 AM EDT
R&D

Arde­lyx rolls out pos­i­tive PhI­II IBS-C da­ta on tena­panor as ri­vals prep for a show­down, but shares crater

John Carroll

Editor & Founder

Two days ago it was Syn­er­gy Phar­ma’s turn to tout pos­i­tive Phase III da­ta on its drug Tru­lance for ir­ri­ta­ble bow­el syn­drome with con­sti­pa­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times